GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Price-to-Free-Cash-Flow

Novo Nordisk A/S (Novo Nordisk A/S) Price-to-Free-Cash-Flow

: 54.92 (As of Today)
View and export this data going back to 1981. Start your Free Trial

As of today (2024-04-19), Novo Nordisk A/S's share price is $122.75. Novo Nordisk A/S's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.24. Hence, Novo Nordisk A/S's Price-to-Free-Cash-Flow Ratio for today is 54.92.

The historical rank and industry rank for Novo Nordisk A/S's Price-to-Free-Cash-Flow or its related term are showing as below:

NVO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.71   Med: 27.71   Max: 58.21
Current: 55.49

During the past 13 years, Novo Nordisk A/S's highest Price-to-Free-Cash-Flow Ratio was 58.21. The lowest was 13.71. And the median was 27.71.

NVO's Price-to-Free-Cash-Flow is ranked worse than
66.67% of 210 companies
in the Biotechnology industry
Industry Median: 29.77 vs NVO: 55.49

Novo Nordisk A/S's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.23. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $2.24.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Novo Nordisk A/S was 10.40% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 34.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 20.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 11.40% per year.

During the past 13 years, Novo Nordisk A/S's highest 3-Year average Free Cash Flow per Share Growth Rate was 130.30% per year. The lowest was -51.70% per year. And the median was 22.00% per year.


Novo Nordisk A/S Price-to-Free-Cash-Flow Historical Data

The historical data trend for Novo Nordisk A/S's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.87 33.43 35.55 33.23 44.82

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.23 36.54 36.79 37.24 44.82

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Price-to-Free-Cash-Flow falls into.



Novo Nordisk A/S Price-to-Free-Cash-Flow Calculation

Novo Nordisk A/S's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=122.75/2.235
=54.92

Novo Nordisk A/S's Share Price of today is $122.75.
Novo Nordisk A/S's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.24.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Novo Nordisk A/S  (NYSE:NVO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Novo Nordisk A/S Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.